Compare AMPH & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMPH | NAVI |
|---|---|---|
| Founded | 1996 | 1973 |
| Country | United States | United States |
| Employees | N/A | 670 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.8M | 802.7M |
| IPO Year | 2005 | N/A |
| Metric | AMPH | NAVI |
|---|---|---|
| Price | $18.18 | $8.46 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 8 | 6 |
| Target Price | ★ $28.38 | $10.00 |
| AVG Volume (30 Days) | 644.5K | ★ 857.1K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 6.73% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $719,887,000.00 | N/A |
| Revenue This Year | $6.90 | $76.23 |
| Revenue Next Year | $4.64 | $15.73 |
| P/E Ratio | $130.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.65 | $7.80 |
| 52 Week High | $31.26 | $16.07 |
| Indicator | AMPH | NAVI |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 48.48 |
| Support Level | $17.03 | $7.83 |
| Resistance Level | $20.08 | $8.79 |
| Average True Range (ATR) | 0.81 | 0.28 |
| MACD | -0.21 | -0.02 |
| Stochastic Oscillator | 19.16 | 51.26 |
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in two segments: Federal Education Loans, and Consumer Lending. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.